Immunocore Holdings plc (NASDAQ:IMCR) Q2 2023 Earnings Call Transcript

Gil Blum: Good morning, everyone, and thanks for taking our question. So this is a bit of a hypothetical at this point, but it’d be interesting to see kind of what you expected the play would be between the PRAME agent and the KIMMTRAK agent in cutaneous melanoma. When you did previously PRAME post KIMMTRAK data and it suggested there was a ton of activity, but what happens the other way around? Thank you.

David Berman: Yes. So in cutaneous mel – so the PRAME after KIMMTRAK was in uveal and although we didn’t see RECIST part response was really remarkable, the disease stabilization that we saw there. Now why was it disease stabilization and not RECIST partial responses like we saw in first line? We don’t know that. We can speculate, but we don’t know. I think we really are excited to study PRAME plus KIMMTRAK to understand how our platform works when you do multiple combinations. It makes sense to study it initially in uveal melanoma because we have a lot of KIMMTRAK experience there. But I think clearly, cutaneous melanoma would be the next step. I think there are two ways to think about it, Gil. One is because both PRAME and gp100 are broadly expressed, we could target more cells within the tumor.

And you could also think for cells that co-express both, there might be more peptide HLA targets on the cell for the T cell to kill. So I think both of those are active hypotheses.

Operator: Thank you. There are no further questions at this time, I would now like to turn the floor back over to Bahija Jallal for any closing comments.

Bahija Jallal: Yes. Thank you, operator. I just want to thank everyone for taking the time today and listening to the progress that we’ve made. So thank you very much.

Operator: Thank you. This does conclude today’s teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.